3:05 PM
 | 
Jan 18, 2018
 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

NYU paper identifies new cancer opportunities for tankyrase inhibitors

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer.

In a Nature Communications study last month, the NYU team conducted proteomic screens in HEK cells with single- and double-knockout of tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS; TNKS1) and TNKS2, and identified 74 targets whose activities were regulated by interaction with one or both enzymes.

Paper author Susan Smith, a professor of pathology at NYU, said that while tankyrases were already known to interact with the Wnt pathway, her study was the first to link them to Notch proteins.

Among the hits were Notch 1 (NOTCH1), Notch...

Read the full 568 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >